Physician profile
Mark Snowise
NPI 1629036116
$3,260.40
in general payments reported to CMS, 2019-2025
34 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $236 · 2021: $407 · 2022: $451 · 2023: $666 · 2024: $354 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $389.91 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $258.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $230.06 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Janssen Pharmaceuticals, INC | $212.41 | 2019-2023 | Spravato, Xarelto |
| Pfizer INC. | $202.78 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $190.33 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $180.99 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $170.23 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Novo Nordisk INC | $165.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $159.18 | 2022-2025 | Qulipta, Ubrelvy |
| Lundbeck LLC | $153.56 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.77 | 2020-2024 | |
| Amgen INC. | $103.99 | 2020-2025 | Repatha, Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $102.38 | 2019-2023 | Eliquis |
| Abbott Laboratories | $84.83 | 2023-2024 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $60.56 | 2019-2020 | |
| Astellas Pharma US INC | $56.80 | 2021-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $48.05 | 2021 | |
| Neurocrine Biosciences, INC. | $38.76 | 2024 | Ingrezza |
| Indivior INC. | $32.85 | 2025 | Sublocade |
| Seqirus USA INC | $31.84 | 2019-2022 | |
| Exact Sciences Corporation | $29.96 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $29.61 | 2023 | Nayzilam |
| Soleno Therapeutics, INC. | $23.84 | 2025 | Vykat Xr |
| Amarin Pharma, INC. | $22.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.77 | 2025 | Zoryve |
| Philips North America LLC | $21.15 | 2023 | |
| Aimmune Therapeutics, INC. | $20.52 | 2025 | Zenpep |
| Scpharmaceuticals INC. | $18.60 | 2025 | |
| Mylan Specialty L.P. | $18.19 | 2022 | |
| Biogen, INC. | $17.25 | 2025 | Skyclarys |
| Sanofi Pasteur INC. | $14.93 | 2025 | |
| Scilex Pharmaceuticals INC. | $13.71 | 2019 | |
| Bioventus LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Snowise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.